Results 41 to 50 of about 9,231 (199)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Leonardo Caires dos Santos, Juliana Corrêa da Costa Ribeiro, Neusa Pereira Silva, Janete Cerutti, Maria Regina Regis da Silva, Maria de Lourdes Lopes Ferrari Chauffaille   +5 more
doaj   +1 more source

Datasheet1_Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity.pdf

, 2022
Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this ...
Marco Spinelli (14065869), Tiziana Angela Coliva (14065872), Sonia Bonanomi (10657052), Fabio Pagni (568040), Fabiola Guerra (14065863), Adriana Balduzzi (14065881), Vincenzo L’Imperio (14065866), Francesco Saettini (10657040), Paola Corti (798510), Giulia Maria Ferrari (14065878), Andrea Biondi (217941), Fabiola Dell’Acqua (14065875)   +11 more
core   +1 more source

Coexistence of immunophenotypically normal and aberrant mast cells in patients with clonal mast cell diseases associates with more indolent subtypes and less severe disease characteristics

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Aberrant antigen expression on mast cells (MCs) is one of the most accurate diagnostic markers for clonal MC diseases (CMCD). Although the coexistence of normal and pathologic MCs is frequently seen, the disease characteristics associated with it have been minimally investigated.
Abdulrazzaq Alheraky, Kees Meijer, Marije Nijk, Saskia K. Klein, Hanneke N. G. Oude Elberink, Ido P. Kema, André B. Mulder   +6 more
wiley   +1 more source

Correlation of cytogenetics and grade of bone marrow fibrosis in primary myelofibrosis [PDF]

Srpski Medicinski Časopis Lekarske Komore
Introduction/Aim: Primary myelofibrosis is a clonal myeloproliferative neoplasm characterized by bone marrow fibrosis and extramedullary hematopoiesis.
Đorđević Vesna, Peruničić-Jovanović Maja, Šefer Dijana, Bižić-Radulović Sandra, Soldatović Ivan, Todorović-Balint Milena   +5 more
doaj   +1 more source

Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series

Head &Neck, EarlyView.
ABSTRACT Introduction A Phase II trial demonstrated that neoadjuvant cemiplimab was associated with pathologic complete response (pCR) in 51% of patients with locoregionally advanced cutaneous squamous cell carcinoma (cuSCC). We evaluated real‐world radiographic and pathologic responses to neoadjuvant cemiplimab and assessed radiologic–pathologic ...
Whitney Jin, Ryan K. Rigsby, Kim Ely, Austin Hoke, Robert Sinard, Kyle Mannion, Jill Gilbert, Lindsay Mundy, Alexander Langerman, Sarah Rohde, Barbara Murphy, Eben Rosenthal, Mitra Mehrad, Michael C. Topf, Jennifer H. Choe   +14 more
wiley   +1 more source

Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase

Haematologica, 2014
Myelofibrosis is a myeloproliferative neoplasm that occurs de novo (primary myelofibrosis) or results from the progression of polycythemia vera or essential thrombocytemia (hereafter designated as secondary myelofibrosis or post-polycythemia vera ...
Mandy Brecqueville, Jérôme Rey, Raynier Devillier, Arnaud Guille, Rémi Gillet, José Adélaide, Véronique Gelsi-Boyer, Christine Arnoulet, Max Chaffanet, Marie-Joelle Mozziconacci, Norbert Vey, Daniel Birnbaum, Anne Murati   +12 more
doaj   +1 more source

Informative Value of Combination of Molecular Genetic and Cytogenetic Diagnostic Methods in Myelofibrosis

, 2016
Introduction. Myelofibrosis is a rare disease affecting myeloid progenitor stem cells. According to the modern criteria of myelofibrosis diagnostics, the confirmation of the clonality of pathological myeloproliferative process is needed.
Voronyak M., Maslyak Z., Lozynska M., Vygovska Ya., Dmytrenko I., Poluben L., Lozynskyy R.   +6 more
core   +1 more source

Therapy-related myelofibrosis does not appear to exist

, 2017
Key Points There is no evidence to support the existence of therapy-related myelofibrosis. Therapy for previous malignancy has no impact on myelofibrosis prognosis.
Taghi Manshouri, Lucia Masarova, Gabriele Todisco, Jorge E. Cortes, Hagop M. Kantarjian, Srdan Verstovsek, Zeev Estrov, Kate J. Newberry   +7 more
core   +1 more source

Myelofibrosis with myeloid metaplasia (MMM) [PDF]

, 1998
Review on Myelofibrosis with myeloid metaplasia (MMM), with data on clinics, and the genes ...
Huret, JL
core   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source